Quantcast

Industry news that matters to you.  Learn more

Sequenom To Explore The Clinical Utility Of A Novel Liquid Biopsy Assay In Melanoma Patients In Collaboration With University Of Colorado Denver

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical collaboration with the University of Colorado Denver, School of Medicine (CU School of Medicine). Under this collaboration, CU School of Medicine will explore the utility of Sequenom’s research use only (RUO) liquid biopsy assay to determine whether ctDNA profiling can be used to monitor treatment response and relapse in melanoma patients. This technology has the potential to overcome the challenges and limitations associated with current methods to monitor treatment response such as invasive biopsies and repeated imaging studies.

Sequenom Collaborates With University Medical Center Hamburg-Eppendorf To Evaluate Clinical Utility Of Liquid Biopsy In Colorectal Cancer

Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical collaboration with University Medical Center Hamburg-Eppendorf (UKE) in Germany. UKE and Sequenom will collaborate to profile circulating cell-free tumor DNA in blood to monitor response to treatment in later stage colorectal cancer patients. This technology has the potential to overcome the challenges and limitations associated with current methods such as imaging, colonoscopy, and invasive biopsies.

Nicox and Sequenom Announce the Launch of Expanded Access to RetnaGene Test Portfolio in the U.S.

Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, and Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative genetic analysis solutions, recently announced that Nicox’s subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories’ RetnaGene™ portfolio of laboratory-developed genetic tests in the United States (U.S.). The RetnaGene portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests, which assess an individual’s risk for advanced age-related macular degeneration (AMD).

Gentris Corporation Launches New Pharmacogenomics Services

Gentris Corporation, a global leader in pharmacogenomics and biorepository services, announced today that it has expanded its genomic biomarker services by incorporating multiple technology platforms into its 24,000 sq. ft., CLIA-certified, GLP-compliant laboratory. Gentris has integrated the Affymetrix GCS3000, Sequenom MassArray, and LifeTech Ion Torrent technologies in a continued effort to identify polymorphisms involved in drug response and adverse drug events as well as in determining somatic mutations in cancer.

NYAS Symposium: Personalized Medicine, a Search for Tailored Therapeutics

The New York Academy of Sciences (NYAS) will be holding an afternoon event later this month that focuses on individualized medicine. Personalized Medicine: A Search for Tailored Therapeutics will be held on Tuesday, September 20th, from 1pm – 5pm EST (10am – 2pm PST). The symposium will also be available via Webinar.